Key facts
- This page summarizes Cormorant Asset Management, LP's Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jul 2021, 16:45.
Cormorant Asset Management, LP - 02 Jul 2021 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)
- Reporting relationship
- Former 10% Owner
- Issuer ticker
- JBIO
- Reported as of
- 02 Jul 2021
- Net transaction value
- +$7,000,000
- SEC form
- 4
- Accepted by SEC
- 07 Jul 2021, 16:45:48 UTC
- Prior SEC filing
- 01 Jul 2021
- Next SEC filing
- 28 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ CORMORANT ASSET MANAGEMENT, LP By : Cormorant Asset Management GP, LLC, its General Partner, By: Bihua Chen, Managing Member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Cormorant Asset Management, LP filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 07 Jul 2021.
Change
- Previous filing in this sequence was filed on 01 Jul 2021.
- Current net transaction value: +$7,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVTE
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,530,691
- Change %
- Price
- Shares after
- 1,530,691
- Date
- 02 Jul 2021
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3
AVTE
transaction
Common Stock
Purchase
- Transaction value
- $7,000,000
- Shares
- +500,000
- Change %
- +33%
- Price
- $14.00
- Shares after
- 2,030,691
- Date
- 02 Jul 2021
- Ownership
- See Footnotes
- Footnotes
- F2, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTE
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,530,691
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Jul 2021
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,530,691
- Exercise price
- Footnotes
- F1, F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Cormorant Asset Management, LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 5 footnotes
Footnote F1
Shares of Series A Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.
Footnote F2
Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund II. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Footnote F3
Represents (i) 318,995 shares of Common Stock held by the Master Fund and (ii) 1,211,696 shares of Common Stock held by Fund II.
Footnote F4
Shares reported herein as purchased on July 2, 2021 represent 500,000 shares purchased by the Master Fund.
Footnote F5
The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 318,995 shares of Common Stock held by the Master Fund and (ii) 1,211,696 shares of Common Stock held by Fund II.